As of December 31, 2023, InflaRx’s total funds available amounted to approximately EUR 98.4 million, comprised of EUR 12.8 million of cash and cash equivalents and EUR 85.7 million of marketable securities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IFRX:
- InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
- IFRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- InflaRx appoints Medina as Head of Investor Relations
- InflaRx price target lowered to $8 from $9 at H.C. Wainwright
- InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
